NCT06282575Phase 3Recruiting

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2028-12-01Estimated

Enrollment · participants286Estimated

Source updated2026-09-14Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Biliary Tract Cancer

Treatments or interventions studied

ZanidatamabDrugAlso known as ZW25, JZP598, ZIIHERA®
CisplatinDrug
GemcitabineDrug
PembrolizumabDrug
DurvalumabDrug

Primary outcomes · main study measures

measure: Progression Free Survival (PFS) in participants with Immunohistochemistry (IHC) 3+ tumors; description: PFS is defined as the time from the date of randomization to the date of documented disease progression, or death from any cause.; timeFrame: Up to 52 months

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history